These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14749677)

  • 1. External validation of a new logistic model in the diagnosis of ovarian cancer.
    Guerriero S; Ajossa S; Boi M; Melis GB
    Am J Obstet Gynecol; 2004 Jan; 190(1):292-3; author reply 293. PubMed ID: 14749677
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Mol et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162-7.
    Timmerman D; Verrelst H; Collins WP; Bourne TH; Vergote I
    Gynecol Oncol; 2001 Oct; 83(1):166-8. PubMed ID: 11585433
    [No Abstract]   [Full Text] [Related]  

  • 3. A prospective validation of the IOTA logistic regression models (LR1 and LR2) in comparison to subjective pattern recognition for the diagnosis of ovarian cancer.
    Nunes N; Ambler G; Hoo WL; Naftalin J; Foo X; Widschwendter M; Jurkovic D
    Int J Gynecol Cancer; 2013 Nov; 23(9):1583-9. PubMed ID: 24088790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent external validation of QCancer (Ovarian).
    Hippisley-Cox J; Coupland C
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):559-60. PubMed ID: 23773163
    [No Abstract]   [Full Text] [Related]  

  • 5. Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model.
    Chen J; Chang C; Huang HC; Chung YC; Huang HJ; Liou WS; Chiang AJ; Teng NN
    Taiwan J Obstet Gynecol; 2015 Aug; 54(4):398-402. PubMed ID: 26384058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting.
    Nunes N; Ambler G; Foo X; Widschwendter M; Jurkovic D
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):829-835. PubMed ID: 28976616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group.
    Van Holsbeke C; Van Calster B; Valentin L; Testa AC; Ferrazzi E; Dimou I; Lu C; Moerman P; Van Huffel S; Vergote I; Timmerman D;
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4440-7. PubMed ID: 17671128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses.
    Van Holsbeke C; Van Calster B; Bourne T; Ajossa S; Testa AC; Guerriero S; Fruscio R; Lissoni AA; Czekierdowski A; Savelli L; Van Huffel S; Valentin L; Timmerman D
    Clin Cancer Res; 2012 Feb; 18(3):815-25. PubMed ID: 22114135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Bogani G; Tagliabue E; Ditto A; Signorelli M; Martinelli F; Casarin J; Chiappa V; Dondi G; Leone Roberti Maggiore U; Scaffa C; Borghi C; Montanelli L; Lorusso D; Raspagliesi F
    Gynecol Oncol; 2017 Oct; 147(1):61-65. PubMed ID: 28779965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying women with undetected ovarian cancer: independent and external validation of QCancer(®) (Ovarian) prediction model.
    Collins GS; Altman DG
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):423-9. PubMed ID: 23121234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models.
    Mol BW; Boll D; De Kanter M; Heintz AP; Sijmons EA; Oei SG; Bal H; Brölmann HA
    Gynecol Oncol; 2001 Feb; 80(2):162-7. PubMed ID: 11161854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the IOTA logistic regression model LR2 for the diagnosis of ovarian cancer.
    Nunes N; Yazbek J; Ambler G; Hoo W; Naftalin J; Jurkovic D
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):355-9. PubMed ID: 22223587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer: can we make the clinical diagnosis earlier?
    Smith LH; Morris CR; Yasmeen S; Parikh-Patel A; Cress RD; Romano PS
    Cancer; 2005 Oct; 104(7):1398-407. PubMed ID: 16116591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    Seebacher V; Aust S; D'Andrea D; Grimm C; Reiser E; Tiringer D; Von Mersi H; Polterauer S; Reinthaller A; Helmy-Bader S
    PLoS One; 2017; 12(8):e0182383. PubMed ID: 28837575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.
    Kaijser J; Bourne T; Valentin L; Sayasneh A; Van Holsbeke C; Vergote I; Testa AC; Franchi D; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2013 Jan; 41(1):9-20. PubMed ID: 23065859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of biomarkers for the ovarian cancer diagnosis.
    Zhang B; Cai FF; Zhong XY
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    Peters IT; van Zwet EW; Smit VT; Liefers GJ; Kuppen PJ; Hilders CG; Trimbos JB
    PLoS One; 2017; 12(1):e0168277. PubMed ID: 28125710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian tumors: prediction of the probability of malignancy by using patient's age and tumor morphologic features with a logistic model.
    Minaretzis D; Tsionou C; Tziortziotis D; Michalas S; Aravantinos D
    Gynecol Obstet Invest; 1994; 38(2):140-4. PubMed ID: 7959343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.